1. Nonobstructive Hypertrophic Cardiomyopathy Out of the Shadows: Known from the Beginning but Largely Ignored … Until Now 
Barry J. Maron, MD, Ethan J. Rowin, MD, Martin S. Maron, MD, Eugene Braunwald, MD 
The American Journal of Medicine 
Volume 130, Issue 2, Pages (February 2017)
DOI: /j.amjmed
Copyright © Terms and Conditions

2. Figure 1
Timeline. Events in hypertrophic cardiomyopathy relevant to developing the principles of nonobstructive vs obstructive disease. HCM = hypertrophic cardiomyopathy.
The American Journal of Medicine  , DOI: ( /j.amjmed )
Copyright © Terms and Conditions

3. Figure 2
Prevalence and risk for advanced heart failure in nonobstructive hypertrophic cardiomyopathy patients (compared with those with rest or provocable obstruction). The proportion of hypertrophic cardiomyopathy patients who develop NYHA functional classes III/IV symptoms, as well as the rate of heart failure progression, is less among nonobstructive hypertrophic cardiomyopathy patients than among those patients with provocable or rest outflow obstruction. NYHA = New York Heart Association functional class; y = year.
The American Journal of Medicine  , DOI: ( /j.amjmed )
Copyright © Terms and Conditions

4. Figure 3
Evolution in understanding the natural history profile in hypertrophic cardiomyopathy. (Left) The present data demonstrate that the vast majority of patients with hypertrophic cardiomyopathy (HCM) do not develop severe progressive heart failure to NYHA functional classes III/IV or require consideration for transplantation (ie, the missing sector). (Right) With the missing sector of the pie inserted, the overall clinical course of HCM is completed, with almost 40% of the cohort represented by stable nonobstructive disease in classes I/II. ASA = alcohol septal ablation; NYHA = New York Heart Association functional class.
The American Journal of Medicine  , DOI: ( /j.amjmed )
Copyright © Terms and Conditions